Bispecific Antibodies to Treat Cancer
Hematologist-oncologist Saad Usmani talks about recent approvals for bispecific antibodies to treat multiple myeloma and other blood cancers.
Progress Against Cancer
Hematologist-oncologist Saad Usmani talks about recent approvals for bispecific antibodies to treat multiple myeloma and other blood cancers.
AI has significant implications for medicine, especially for precision cancer care.
Childhood cancer survivors have a higher risk of developing depression and anxiety, and more news selected by the editors of Cancer Today.
According to an annual Gallup poll that surveys approximately 10,000 U.S. adults, 7.2% of Americans aged 18 and older identified as lesbian, gay, bisexual, transgender, queer, intersex, asexual, or anything other than heterosexual and...
New treatments have changed care for multiple myeloma, and more new selected by the editors of Cancer Today.
The FDA granted full approval to blinatumomab for certain patients with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration (FDA) has approved blinatumomab (Blincyto) for the treatment of adult and pediatric patients...
The FDA approved the PARP inhibitor talazoparib in combination with hormone therapy for metastatic prostate cancer The U.S. Food and Drug Administration (FDA) has approved talazoparib (Talzenna) in combination with the antiandrogen therapy enzalutamide...
Women diagnosed with early-stage breast cancer are more likely to live five years or longer compared with those diagnosed in earlier decades, and more.
The FDA granted accelerated approval to another bispecific T-cell engager to treat certain B-cell lymphomas The U.S. Food and Drug Administration (FDA) has granted accelerated approval to glofitamab-gxbm (Columvi) for select patients with B-cell...
Daily pill lowers lung cancer death rate, the FDA authorizes importing shortage-affected cancer drugs from China, and more.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More